Australian biotech Microba brings gut analysis to Europe with SYNLAB

Latest News

Brisbane-based Microba has partnered with Europe’s largest medical diagnostic services provider, SYNLAB, to deliver its gut microbiome analysis into Europe.

Microba said the partnership will bring together its metagenomics sequencing and bioinformatics with SYNLAB’s laboratory services team to deliver new gastrointestinal analysis services to their network of practising doctors and clinics.

Microba was developed out of research from the University of Queensland. It launched Australia’s first detailed gut microbiome analysis in June 2018. 

The company said it has assisted more than 10,000 Australians to assess their gut health individually or with the help of a healthcare professional.

SYNLAB is the market leader in medical diagnostic services in Europe. It has a presence in more than 40 countries.

The co-delivered MyBiome gut microbiome analysis will be initially launched in two countries.

“Microba’s partnership with SYNLAB is a great example of two international forces joining together to embrace next-generation technologies and support local healthcare,” said Microba CEO Blake Wills

“It will allow us to expand the reach of our technology into the European market, and bring innovation born in Australia into larger overseas markets to positively impact more lives,” he added.

Mr Wills said delivering an analysis into the European market in partnership with SYNLAB will allow Microba to access large and established markets with unmet demand for comprehensive microbiome analysis services.

“SYNLAB is a global leader in delivering medical diagnostic services and we are proud to be partnering to add advanced gut microbiome analysis to their portfolio, powered by Microba’s technology,” he said.

Chief medical officer of SYNLAB Group, Dr Santiago Valor, said, “We are excited to start this collaboration with Microba. SYNLAB’s commitment to medical excellence in diagnostics is underlined by complementing our test portfolio with the MyBiome analysis.

“Together we set a sign for continuous medical advancement to the benefit of patients and customers.”